© 2021 MJH Life Sciences and HCPLive - Clinical news for connected physicians. All rights reserved.
© 2021 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
Insight from gastroenterology specialists on implications for treating patients with ulcerative colitis with newer novel therapies as recently presented at DDW 2021.
June 4th 2021
Andres Yarur, MD, of the Medical College of Wisconsin, comments on the chronic, progressive nature of ulcerative colitis and highlights special considerations for classifying patients based on disease severity.
June 11th 2021
Treatment recommendations for patients with ulcerative colitis as outlined by the American College of Gastroenterology clinical practice guidelines.
Maria T. Abreu, MD, of the University of Miami Health System, explains how goals of treatment for ulcerative colitis have changed in recent years and reacts to changes in managing the disease.
June 18th 2021
Drs Maria T. Abreu and Andres Yarur briefly review current treatment options used to manage patients with ulcerative colitis.
Limitations that physicians and patients face when selecting therapy for ulcerative colitis.
June 23rd 2021
Implications for treating patients with ulcerative colitis with novel S1P receptor modulators based on data revealed by the phase 2 OASIS trial, which has now led to a phase 3 study, ELEVATE UC 52.
Drs Maria T. Abreu and Timothy Ritter comment on limitations faced by providers who treat patients with ulcerative colitis and highlight strategies under investigation that can improve how the disease is managed.
Advice for community physicians and gastroenterologists to help manage patients with ulcerative colitis.